INmune Bio (NASDAQ:INMB) Azioni, Quote.MetaTitle.unusual-options

INmune Bio

INmune Bio Inc

Aligos Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

BioAtla

Celularity

CEL-SCI

Evaxion

FibroGen

Generation Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kezar Life Sciences

Lantern Pharma

LAVA Therapeutics

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Pluri

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

RenovoRx

Serina Therapeutics

Skye Bioscience

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty

8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th

INmune Bio (INMB) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

Comments

INmune Bio Opzioni Inusuali

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO